Study Description
Screening
Study Centers
Contact/Consent
Chronic Obstructive Pulmonary Disease (COPD)
Two major diseases contribute to COPD: emphysema and chronic bronchitis. The chief symptoms are chronic cough, spitting or coughing up mucus (expectoration), breathlessness on exertion, and progressive reduction in the ability to breathe out fully. Cigarette smoking accounts for 82% of COPD deaths.
Novartis is seeking people to participate in a clinical trial(s) testing the safety
and effectiveness of Novartis products. Novartis recommends that you consult your
doctor before participating in a clinical trial.
For more information about clinical trial participation, click here. Also, for additional information
about how Novartis helps to protect the privacy of the personal information that you provide to us, please
see the Novartis Privacy Policy.
Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits
your (or the participant's) condition.
COPD Study CNVA237A2303
The purpose of this clinical trial is to determine the long term benefits and safety of the investigative drug NVA237 as a once daily treatment in people with moderate to severe chronic obstructive pulmonary disease (COPD). “An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).”
Trial phase: Phase 3
Participation Duration: Participants in this study will be asked to visit the study center 18 times over a 1 year period.
Protocol Number: CNVA237A2303
|